Sectors
CTMX
CytomX Therapeutics, Inc.
3.36
2 x 2.43
2 x 4.07
bid
ask
+
0.15
4.67%
2 @ 07:30 PM
3.36 +0.00 (0.00%)
| Ytd | -21.13% | |
| 1y | 64.71% |
3.17
day range
3.37
1.90
52 week range
8.21
| Open | 3.20 | Prev Close | 3.21 | Low | 3.17 | High | 3.37 | Mkt Cap | 732.14M |
| Vol | 2.38M | Avg Vol | 3.95M | EPS | -0.57 | P/E | N/A | Forward P/E | -9.74 |
| Beta | 2.48 | Short Ratio | 1.78 | Inst. Own | 75.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 3.44 | 200-d Avg | 4.16 | 1yr Est | 13.67 |
| Income Statement | |||
| Total Revenue | 1.42M | ||
| Revenues (USD) | 1.42M | ||
| Gross Profit | 1.42M | ||
| Operating Expenses | 25.20M | ||
| Research and Development Expense | 17.60M | ||
| Selling, General and Administrative Expense | 7.60M | ||
| Operating Income | -23.78M | ||
| Income Tax Expense | 60.00K | ||
| Net Income | -20.67M | ||
| Net Income Common Stock | -20.67M | ||
| Net Income Common Stock (USD) | -20.67M | ||
| Consolidated Income | -20.67M | ||
| Earnings per Basic Share | -0.09 | ||
| Earnings per Basic Share (USD) | -0.09 | ||
| Earnings per Diluted Share | -0.09 | ||
| Earning Before Interest & Taxes (EBIT) | -20.61M | ||
| Earning Before Interest & Taxes (USD) | -20.61M | ||
| Weighted Average Shares | 218.94M | ||
| Weighted Average Shares Diluted | 218.94M | ||
| Balance Sheet | |||
| Cash and Equivalents | 18.75M | ||
| Cash and Equivalents (USD) | 18.75M | ||
| Investments | 313.06M | ||
| Investments Current | 313.06M | ||
| Trade and Non-Trade Receivables | 37.49M | ||
| Current Assets | 373.16M | ||
| Property, Plant & Equipment Net | 6.12M | ||
| Total Assets | 381.23M | ||
| Debt Current | 1.50M | ||
| Total Debt | 5.70M | ||
| Current Liabilities | 39.86M | ||
| Debt Non-Current | 4.21M | ||
| Total Liabilities | 79.16M | ||
| Accumulated Retained Earnings (Deficit) | -750.86M | ||
| Accumulated Other Comprehensive Income | -196.00K | ||
| Shareholders Equity | 302.07M | ||
| Shareholders Equity (USD) | 302.07M | ||
| Assets Non-Current | 8.07M | ||
| Total Debt (USD) | 5.70M | ||
| Deferred Revenue | 54.69M | ||
| Goodwill and Intangible Assets | 1.31M | ||
| Liabilities Non-Current | 39.30M | ||
| Trade and Non-Trade Payables | 1.94M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.41M | ||
| Net Cash Flow from Financing | 511.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -11.60M | ||
| Issuance (Purchase) of Equity Shares | 511.00K | ||
| Net Cash Flow from Investing | 5.95M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 5.95M | ||
| Net Cash Flow from Operations | -18.07M | ||
| Share Based Compensation | 2.58M | ||